Physician profile
Jeffrey Berman
NPI 1801855721
$2,540.14
in general payments reported to CMS, 2019-2025
20 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $37.32 · 2021: $520 · 2022: $561 · 2023: $190 · 2024: $160 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,103.20 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $210.35 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.47 | 2019-2022 | |
| Amgen INC. | $157.34 | 2019-2020 | |
| Edwards Lifesciences Corporation | $150.00 | 2025 | Pascal |
| Heartflow, INC. | $147.59 | 2025 | |
| Lilly USA, LLC | $135.30 | 2025 | Jardiance, Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $127.53 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $48.80 | 2019 | |
| Esperion Therapeutics, INC. | $48.23 | 2024-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.09 | 2020-2025 | Lifevest |
| Abiomed | $37.07 | 2025 | |
| Pfizer INC. | $32.73 | 2019-2024 | |
| Janssen Biotech, INC. | $26.31 | 2022 | |
| Merck Sharp & Dohme LLC | $22.41 | 2025 | Verquvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $21.12 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.40 | 2019 | |
| Glaxosmithkline, LLC. | $18.12 | 2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $15.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.